Description
Pharmacological action
Bravecto refers to systemic insecticaricidal drugs. Fluralaner, which is part of the drug – (4- [5- (3, 5-dichlorophenyl) -5- (trifluoromethyl) -4H-isoxazol-3-yl] -2-methyl-N- [2-oxo-2- (2,2,2-trifluoroethylamino) ethyl] benzamide) – isoxazoline group insectoacaricide , is active against fleas (Ctenocephalides felis and Ctenocephalides canis) and ticks (adults and larvae of Ixodes ricinus, Ixodes hexagonus, Ixodes scapularis, Ixodes holocyclus, Dermacentoricus variabilisus, and Dermacentoricus variabilisus and. The mechanism of action of fluralaner is to block GABA-dependent and glutamate-dependent arthropod receptors, hyper-excitation of neurons, impaired transmission of nerve impulses, which leads to paralysis and death of ectoparasites. After oral administration of the drug, fluralaner is easily absorbed in the gastrointestinal tract and reaches the systemic circulation, maximum plasma concentration is reached within 1 day, bioavailability is 20-27%, feed intake accelerates absorption. It is excreted fluralandermally, mainly in unchanged form with feces (~ 90% of the dose) and partially with urine, the elimination half-life is 12 days. The drug begins to act 4 hours after application and causes the death of fleas 8 hours after attachment to the body of the host, ticks – 12 hours later, preventing re-infection of dogs with ectoparasites. The death of fleas occurs before the laying of eggs, which prevents contamination of the premises with eggs and larvae.
According to the degree of exposure to the body, Bravecto belongs to the “low hazard” substances (hazard class 4 according to GOST 12.1.007-76), at the recommended doses it does not have an embryotoxic, teratogenic, mutagenic effect.
Indications
Bravecto is prescribed for dogs for the treatment and prevention of aphanipherosis, in the treatment of flea-induced allergic dermatitis, acaroses caused by ixodid ticks, for the treatment of demodicosis, sarcoptosis and otodectosis, as well as to reduce the risk of babesiosis.
Contraindications
Contraindication to use is individual intolerance to the components of the drug. The drug should not be used for puppies younger than 8 weeks of age and / or dogs weighing less than 2 kg. Bravecto is not intended for use by productive animals.
Directions for use
Doses of the drug depending on the weight of the animal
Dog weight, kg Dose of the drug (mg / pipette), number of pipettes
2 – 4.5 Bravecto 112.5 mg
4.5 – 10 Bravecto 250 mg
> 10 – 20 Bravecto 500 mg
> 20 – 40 Bravecto 1000 mg
> 40 – 56 Bravecto 1400 mg
Protects the animal from fleas and ticks for up to 12 weeks. When using the drug for dogs weighing more than 56 kg, a combination of pipettes is used.
Special instructions
There are no specific effects on the first use of the drug and its withdrawal. With the simultaneous use of Bravecto with anthelmintics, antibiotics, non-steroidal anti-inflammatory drugs and glucocorticosteroids, undesirable reactions and a decrease in the effectiveness of the drug were not detected.
Composition
As action The active substance fluralaner, in 1 pipette – 250 mg.
Side effects
Side effects and complications when using the drug in accordance with the instructions, as a rule, are not observed. In rare cases, vomiting, diarrhea, loss of appetite and salivation are possible. If the dog has vomited within the first two hours after taking Bravecto, it is recommended to make sure that the vomiting has stopped and give the drug again in the same dose.
dosage form
solution for external use
